中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.024 seconds)

    VACUNAS ANTICANCER DE GLOBO H Y RELACIONADAS CON ADYUVANTES DE GLUCOLIPIDO NOVEDOSOS.
    21.
    发明专利
    VACUNAS ANTICANCER DE GLOBO H Y RELACIONADAS CON ADYUVANTES DE GLUCOLIPIDO NOVEDOSOS. 未知

    公开(公告)号：MX2010013932A

    公开(公告)日：2013-03-01

    申请号：MX2010013932

    申请日：2009-08-06

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU JOHN ,  YU ALICE

    IPC: A61K39/00 ,  A61K39/385

    Abstract: Se proporcionan composiciones inmunogénicas, vacunas de cáncer y métodos para tratar cáncer. Se proporcionan composiciones que comprenden: (a) un glicano tal como Globo H o un fragmento inmunogénico del mismo, en donde el glicano está conjugado con una proteína portadora mediante un enlazador tal como para-nitrofenilo; y (b) un adyuvante que comprende glucolípido capaz de enlazar CDId sobre una célula dendrítica, tal como un derivado de a-galactosilceramida, en donde la composición inmunogénica induce una respuesta inmune que induce un nivel relativo más alto de anticuerpos de isotipo IgG como es comparado con los anticuerpos de isotipo IgM. Se proporcionan composiciones inmunogénicas que comprenden el material de reacción cruzada de toxina de difteria de proteína portadora 197 (DT-CRM 197) y el adyuvante C34. Los anticuerpos generados por las composiciones inmunogénicas divulgadas en la presente además neutralizan por lo menos uno de los antígenos Globo H, antígeno embriónico específico de etapa-3 (SSEA-3) y antígeno embriónico específico de etapa-4 (SSEA-4). Terapias contra células madre de cáncer de seno que comprenden composiciones inmunogénicas que comprenden Globo H, SSEA-3 o SSEA-4 conjugado con DT-CRM 197.

    GLOBO H AND STAGE SPECIFIC EMBRYONIC ANTIGENS AND Bb4 AND RELATED ANTI-CANCER VACCINES WITH NOVEL GLYCOLIPID ADJUVANTS
    22.
    发明专利
    GLOBO H AND STAGE SPECIFIC EMBRYONIC ANTIGENS AND Bb4 AND RELATED ANTI-CANCER VACCINES WITH NOVEL GLYCOLIPID ADJUVANTS 未知

    公开(公告)号：NZ590140A

    公开(公告)日：2012-07-27

    申请号：NZ59014009

    申请日：2009-08-06

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

    IPC: A61K39/00 ,  A61K39/385

    Abstract: Disclosed is an immunogenic composition comprising: (a) a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker; and (b) an adjuvant including C34, wherein C34 is defined in the specification. Also disclosed is the use of the immunogenic composition in the manufacture of a medicament for the treatment or inhibition of tumor growth, wherein administration of medicament induces au immune response that produces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies.

    GLOBO H AND RELATED ANTI-CANCER VACCINES WITH NOVEL GLYCOLIPID ADJUVANTS
    23.
    发明专利
    GLOBO H AND RELATED ANTI-CANCER VACCINES WITH NOVEL GLYCOLIPID ADJUVANTS 未知

    公开(公告)号：CA2728341A1

    公开(公告)日：2010-01-14

    申请号：CA2728341

    申请日：2009-08-06

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  YU ALICE ,  YU JOHN

    IPC: A61K39/00 ,  A61K39/385

    Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer are provided. Compositions comprising: (a) a glycan such as Globo H or an immunogenic fragment thereof, wherein the glycan is conjugated with a carrier protein by a linker such as para-nitrophenyl; and (b) an adjuvant comprising glycolipid capable of binding CDId on a dendritic cell, such as an a-galactosyl-ceramide derivative, wherein the immunogenic composition induces an immune response that induces a higher relative level of IgG isotype antibodies as compared to IgM isotype antibodies, are provided. Immunogenic compositions comprising the carrier protein diphtheria toxin cross-reacting material 197 (DT-CRM 197) and the adjuvant C34 are provided. Antibodies generated by immunogenic compositions disclosed herein further neutralize at least one of the antigens Globo H, stage-specific embryonic antigen-3 (SSEA-3) and stage-specific embryonic antigen-4 (SSEA-4). Therapeutics against breast cancer stem cells comprising immunogenic compositions comprising Globo H, SSEA-3 or SSEA-4 conjugated with DT-CRM 197.

    ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES
    26.
    发明专利
    ALPHA-GALACTOSYL CERAMIDE ANALOGS AND THEIR USE AS IMMUNOTHERAPIES 未知

    公开(公告)号：CA2683681A1

    公开(公告)日：2008-10-23

    申请号：CA2683681

    申请日：2008-04-14

    Applicant: ACADEMIA SINICA

    Inventor： WONG CHI-HUEY ,  YU ALICE ,  CHANG YA-JEN

    IPC: A61K8/42 ,  A61K8/00 ,  C07C235/80 ,  C07C237/10

    Abstract: The present disclosure relates to synthetic alpha-galactosyl ceramide (.a lpha.-GalCer) analogs, and their use as immunotherapies. In one aspect, a me thod of activating a cytokine response in a subject includes administering a n effective amount of a compound to a subject, wherein the subject has an ad aptive immune system that includes a population of cells, the population inc luding at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula (1) wherein , n is 0 to 25; X is selected from O and S; R1is selected from H, CH3, and p henyl, where phenyl is optionally substituted with H, OH, OCH3, F, CF3, phen yl, phenyl-F, C1-C6 alkyl, or C2-C6 branched alkyl; R2 is selected from OH a nd H; R3 is selected from C1-C15 alkyl, and phenyl, where phenyl is optional ly substituted with H, OH, OCH3, F, CF3, phenyl, C1-C6 alkyl, or C2-C6 branc hed alkyl; R4 is selected from OH, OSO3H, OSO3Na, and OSO3K; and R5 is selec ted from CH2OH and CO2H; or a pharmaceutically acceptable salt thereof; form ing a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytokine response.

Patent Agency Ranking